<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02299050</url>
  </required_header>
  <id_info>
    <org_study_id>HSC20130330H</org_study_id>
    <nct_id>NCT02299050</nct_id>
  </id_info>
  <brief_title>Effect of Cycloset on Glycemic Control When Added to Glucagon-like Peptide 1 (GLP-1) Analogue Therapy</brief_title>
  <official_title>Effect of Cycloset on Glycemic Control in Type 2 Diabetic Patients Inadequately Controlled on GLP-1 Analogue Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The University of Texas Health Science Center at San Antonio</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>VeroScience</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>The University of Texas Health Science Center at San Antonio</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Purpose This study will examine the effect of the addition of Cycloset upon glucose
      metabolism (glycemic control including post prandial glucose metabolism) in individuals with
      inadequately controlled (HbA1c 7.5-10.0) type 2 diabetes (T2DM) who are already on Bydureon
      (exenatide once weekly) or Victoza (liraglutide once daily) as part of their standard care.

      Both a mechanistic rationale and empirical experimental evidence implicate a beneficial
      interaction between bromocriptine and the incretin mimetics (GLP-1 analogs) upon postprandial
      hyperglycemia in insulin resistant states. One of the actions of the incretin mimetics such
      as the GLP-1 analogs is to stimulate postprandial beta cell insulin secretory response to
      plasma glucose (see drug labeling information; www.fda.gov). Thus the combination of Cycloset
      that is working as a post prandial insulin sensitizier with therapies that increase post
      prandial insulin would be expected to provide complimentary glucose lowering effects. To
      date, however, no such studies investigating the interactive effects of a GLP-1 analog and
      Bromocriptine-QR (QR=extended release) (Cycloset) have been conducted in humans.

      Condition - Type 2 Diabetes. Intervention - Cycloset. Phase - Phase 4

      Study Type: Interventional Study Design: Treatment, Single Group Assignment, Open Label, N/A,
      Safety/Efficacy Study

      Official Title: Effect of Cycloset on Glycemic Control in Type 2 Diabetic Patients
      Inadequately Controlled on GLP-1 Analogue Therapy
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a single-site, prospective, cohort study that will assess the effect of Cycloset as
      add-on therapy in adult subjects with T2DM that is inadequately controlled (HbA1c 7.5% to
      10.0%) on GLP-1 analog therapy with either exenatide (Bydureon) once weekly or liraglutide
      (Victoza) once daily.

      Entry criteria will be checked at the screening visit. All qualified subjects will undergo
      baseline studies including non-invasive hemodynamic testing for assessment of aortic
      stiffness and pulse wave velocity, assessment of body weight composition by dual-energy X-ray
      absorptiometry (DXA), assessment of endothelial function using the Endo-PAT device,
      measurement of cytokines and inflammatory biomarkers in the peripheral blood and urine,
      assessment of oxidative stress and inflammatory markers in white blood cells isolated from a
      peripheral whole blood sample, a 5-hour mixed meal tolerance test (MMT) for assessment of
      postprandial glucose metabolism and 24-hour ambulatory BP monitoring.

      Following completion of all the baseline studies as above, subjects will be started on
      Cycloset, 0.8 mg/day in addition to their stable dose of Bydureon (exenatide) (2mg/week) or
      Victoza (liraglutide) (1.2-1.8 mg/day), and the dose will be increased by 0.8 mg/day every
      week to a maximum of 3.2 mg/day, or as tolerated to a minimum of 2.4 mg/day.

      Subjects will return at months 1, 2, 3, and 4 for interim medical history, body weight,
      HbA1c, and FPG (Fasting plasma glucose). Postural blood pressure measurements will be
      obtained with the subject lying down and then after standing for 5 minutes at each of the
      visits. At month 4, all of the baseline studies detailed above will be repeated.

      All tests will be performed in the Clinical Research Center at the Texas Diabetes
      Institute/University of Texas Health Science Center, San Antonio.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2014</start_date>
  <completion_date type="Actual">April 30, 2018</completion_date>
  <primary_completion_date type="Actual">April 30, 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>HbA1C</measure>
    <time_frame>Change from baseline to four to five months</time_frame>
    <description>The objective of this study is to examine the effect of the addition of Cycloset on glycemic control in inadequately controlled (HbA1c 7.5-10.0) T2DM (type 2 diabetes mellitus) patients who are already on Bydureon (exenatide once weekly) or Victoza (liraglutide ) as part of their standard care.
An additional co-primary objective of the study is to examine the effect of Cycloset on postprandial glucose metabolism.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Glucose Metabolism During Mixed Meal Tolerance Test</measure>
    <time_frame>Change from baseline to four to five months</time_frame>
    <description>The objective of this study is to examine the effect of the addition of Cycloset on glycemic control in inadequately controlled (HbA1c 7.5-10.0) T2DM patients who are already on Bydureon (exenatide once weekly) or Victoza (liraglutide ) as part of their standard care.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Endothelial Function,</measure>
    <time_frame>Change from baseline to four to five months</time_frame>
    <description>To assess the potential beneficial effect of Cycloset on endothelial function. This is measured by using pulse pressure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body Composition</measure>
    <time_frame>Change from baseline to four to five months</time_frame>
    <description>To assess the potential beneficial effect of Cycloset on body weight composition.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage Body Fat</measure>
    <time_frame>Change from baseline to four to five months</time_frame>
    <description>To assess the potential beneficial effect of Cycloset on body fat content</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood Pressure</measure>
    <time_frame>Change from baseline to four to five months</time_frame>
    <description>To assess the potential beneficial effect of Cycloset on blood pressure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Arterial Blood Pressure</measure>
    <time_frame>Change from baseline to four to five months</time_frame>
    <description>To assess the potential beneficial effect of Cycloset on change in mean arterial blood pressure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Arterial Stiffness (AS)</measure>
    <time_frame>Change from baseline to four to five months</time_frame>
    <description>To assess the potential beneficial effect of Cycloset on arterial stiffness. Arterial stiffness is calculated by the measurement of pulse pressure, where Pulse pressure = SBP - DBP (Where SBP is systolic blood pressure and DBP is diastolic blood pressure) The calculated value is used as a predictor of cardiovascular disease. Higher values indicate that cardiovascular disease is more likely.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">23</enrollment>
  <condition>Type 2 Diabetes</condition>
  <arm_group>
    <arm_group_label>Cycloset</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Drug - Cycloset Cycloset 2.4 -3.2 mg/day
Other Names:
Bromocriptine Mesylate Quick Release</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cycloset</intervention_name>
    <description>Bromocriptine QR 0.8 mg tablet 0.8 mg/day with dose increased to a maximum of 3.2 mg/day or as tolerated to a minimum of 2.4 mg/day Other names: Cycloset, B-QR</description>
    <arm_group_label>Cycloset</arm_group_label>
    <other_name>Bromocriptine Mesylate Quick Release</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Type 2 diabetes male or female subjects between the ages of 30 and 70 years of age,
             inclusive, at Screening

          -  BMI = 24-40 kg/m2

          -  HbA1c = 7.5-10.0%

          -  Stable body weight (Â±3-4lbs) over the preceding 3 months

          -  Subjects currently receiving a stable dose of exenatide (2mg/week) or liraglutide
             (1.2-1.8 mg/day) for at least 90 days prior to determination of baseline HbA1C and
             eligibility for enrollment in the study protocol.

          -  Subjects with a daytime feeding/night time sleeping schedule

          -  Subjects with no evidence of major organ system disease as determined by physical
             exam, history, and screening laboratory data

          -  Women must be of non-childbearing potential as defined by one of the following:

          -  Women &gt;45 and &lt; 60 years of age at Screening, who have been amenorrheic for at least 2
             years

          -  Women who have had a documented hysterectomy and/or bilateral oophorectomy

          -  Women &gt; 60 years of age

          -  Females of childbearing potential with a negative pregnancy test at Screening and
             Treatment visits, using one of the following forms of contraception for the duration
             of participation in the study (i.e., until Follow-up 7-14 days post last dose): Oral
             contraceptive, Injectable progesterone, subdermal implant, spermicidal
             foam/gel/film/cream/suppository, diaphragm with spermicide, copper or hormonal
             containing IUD (intrauterine device), sterile male partner vasectomized &gt; 6 month
             pre-dosing

          -  Evidence of a personally signed and dated informed consent document indicating that
             the subject has been informed of all pertinent aspects of the study

          -  Subjects must be willing and able to comply with scheduled visits, treatment,
             laboratory tests and study procedures.

        Exclusion Criteria:

          -  Recent (i.e., within three (3) months prior to Screening) evidence or medical history
             of unstable concurrent disease such as: documented evidence or history of clinically
             significant hematological, endocrine, pulmonary, gastrointestinal, cardiovascular,
             hepatic, psychiatric, immunological, or clinically significant neurological disease.

          -  No history of T2DM

          -  BMI of less 24 and greater 40 kg/m2

          -  Unstable body weight (change of greater than Â±3-4lbs over the preceding 3 months

          -  Subjects not currently receiving exenatide or liraglutide

          -  Subjects participating in an excessively heavy exercise program

          -  Subject with a feeding/sleeping schedule different from a daytime feeding/night time
             sleeping schedule

          -  Subjects taking medications known to alter glucose metabolism (with the exception of
             metformin and/or pioglitazone) or which effect brain neuro synaptic function are
             excluded.

          -  Subjects with evidence of major organ system disease as determined by physical exam,
             history, and screening laboratory data

          -  Pregnant subjects or subjects unwilling to use birth control during their study
             enrollment

          -  Blood donation of approximately 1 pint (500 mL) within 8 weeks prior to Screening 12.
             Subjects that are allergic to bromocriptine or any of the other ingredients in
             Cycloset, or take ergot medicines, breastfeeding or have history of syncope or Type 1
             diabetes mellitus

          -  Other severe acute or chronic medical or psychiatric condition or laboratory
             abnormality that may increase the risk associated with study participation or
             investigational product administration or may interfere with the interpretation of
             study results that, in the judgment of the investigator, would make the subject
             inappropriate for entry into this study subjects of reproductive potential
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>69 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ralph A DeFronzo, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The University of Texas Health Science Center at San Antonio</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Texas Health Science Center</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://onlinelibrary.wiley.com/doi/full/10.1002/edm2.34</url>
    <description>Endocrinology, Diabetes &amp; Metabolism 15 August 2018</description>
  </link>
  <verification_date>May 2019</verification_date>
  <study_first_submitted>September 16, 2014</study_first_submitted>
  <study_first_submitted_qc>November 19, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 24, 2014</study_first_posted>
  <results_first_submitted>April 30, 2019</results_first_submitted>
  <results_first_submitted_qc>June 20, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">June 21, 2019</results_first_posted>
  <last_update_submitted>June 20, 2019</last_update_submitted>
  <last_update_submitted_qc>June 20, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">June 21, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Type 2 Diabetes</keyword>
  <keyword>T2DM</keyword>
  <keyword>Cycloset</keyword>
  <keyword>Glycemic Control</keyword>
  <keyword>GLP-1</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bromocriptine</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>June 3, 2015</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/50/NCT02299050/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Cycloset</title>
          <description>Drug - Cycloset Cycloset 2.4 -3.2 mg/day
Other Names:
Bromocriptine Mesylate Quick Release
Cycloset: Bromocriptine QR 0.8 mg tablet 0.8 mg/day with dose increased to a maximum of 3.2 mg/day or as tolerated to a minimum of 2.4 mg/day Other names: Cycloset, B-QR</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="23"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Subjects who were consented and received study intervention</population>
      <group_list>
        <group group_id="B1">
          <title>Cycloset</title>
          <description>Drug - Cycloset Cycloset 2.4 -3.2 mg/day
Other Names:
Bromocriptine Mesylate Quick Release
Cycloset: Bromocriptine QR 0.8 mg tablet 0.8 mg/day with dose increased to a maximum of 3.2 mg/day or as tolerated to a minimum of 2.4 mg/day Other names: Cycloset, B-QR</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="15"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <title>Participants age</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="57" spread="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Medications currently used for type 2 diabetes</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Liraglutide (1.2 - 1.8 mg/d)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Metformin</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Low dose glargine insulin</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>HbA1C</title>
        <description>The objective of this study is to examine the effect of the addition of Cycloset on glycemic control in inadequately controlled (HbA1c 7.5-10.0) T2DM (type 2 diabetes mellitus) patients who are already on Bydureon (exenatide once weekly) or Victoza (liraglutide ) as part of their standard care.
An additional co-primary objective of the study is to examine the effect of Cycloset on postprandial glucose metabolism.</description>
        <time_frame>Change from baseline to four to five months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Cycloset</title>
            <description>Drug - Cycloset Cycloset 2.4 -3.2 mg/day
Other Names:
Bromocriptine Mesylate Quick Release
Cycloset: Bromocriptine QR 0.8 mg tablet 0.8 mg/day with dose increased to a maximum of 3.2 mg/day or as tolerated to a minimum of 2.4 mg/day Other names: Cycloset, B-QR</description>
          </group>
        </group_list>
        <measure>
          <title>HbA1C</title>
          <description>The objective of this study is to examine the effect of the addition of Cycloset on glycemic control in inadequately controlled (HbA1c 7.5-10.0) T2DM (type 2 diabetes mellitus) patients who are already on Bydureon (exenatide once weekly) or Victoza (liraglutide ) as part of their standard care.
An additional co-primary objective of the study is to examine the effect of Cycloset on postprandial glucose metabolism.</description>
          <units>mmol/mol</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline Measurement</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.3" spread="0.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Measurement at 4-5 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.7" spread="0.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Glucose Metabolism During Mixed Meal Tolerance Test</title>
        <description>The objective of this study is to examine the effect of the addition of Cycloset on glycemic control in inadequately controlled (HbA1c 7.5-10.0) T2DM patients who are already on Bydureon (exenatide once weekly) or Victoza (liraglutide ) as part of their standard care.</description>
        <time_frame>Change from baseline to four to five months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Cycloset</title>
            <description>Drug - Cycloset Cycloset 2.4 -3.2 mg/day
Other Names:
Bromocriptine Mesylate Quick Release
Cycloset: Bromocriptine QR 0.8 mg tablet 0.8 mg/day with dose increased to a maximum of 3.2 mg/day or as tolerated to a minimum of 2.4 mg/day Other names: Cycloset, B-QR</description>
          </group>
        </group_list>
        <measure>
          <title>Glucose Metabolism During Mixed Meal Tolerance Test</title>
          <description>The objective of this study is to examine the effect of the addition of Cycloset on glycemic control in inadequately controlled (HbA1c 7.5-10.0) T2DM patients who are already on Bydureon (exenatide once weekly) or Victoza (liraglutide ) as part of their standard care.</description>
          <units>mg/kg *min</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline Measurement</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.1" spread="0.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Measurement at 4-5 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.7" spread="0.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Endothelial Function,</title>
        <description>To assess the potential beneficial effect of Cycloset on endothelial function. This is measured by using pulse pressure.</description>
        <time_frame>Change from baseline to four to five months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Cycloset</title>
            <description>Drug - Cycloset Cycloset 2.4 -3.2 mg/day
Other Names:
Bromocriptine Mesylate Quick Release
Cycloset: Bromocriptine QR 0.8 mg tablet 0.8 mg/day with dose increased to a maximum of 3.2 mg/day or as tolerated to a minimum of 2.4 mg/day Other names: Cycloset, B-QR</description>
          </group>
        </group_list>
        <measure>
          <title>Endothelial Function,</title>
          <description>To assess the potential beneficial effect of Cycloset on endothelial function. This is measured by using pulse pressure.</description>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline Measurement</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54" spread="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Measurement at 4-5 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51" spread="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Body Composition</title>
        <description>To assess the potential beneficial effect of Cycloset on body weight composition.</description>
        <time_frame>Change from baseline to four to five months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Cycloset</title>
            <description>Drug - Cycloset Cycloset 2.4 -3.2 mg/day
Other Names:
Bromocriptine Mesylate Quick Release
Cycloset: Bromocriptine QR 0.8 mg tablet 0.8 mg/day with dose increased to a maximum of 3.2 mg/day or as tolerated to a minimum of 2.4 mg/day Other names: Cycloset, B-QR</description>
          </group>
        </group_list>
        <measure>
          <title>Body Composition</title>
          <description>To assess the potential beneficial effect of Cycloset on body weight composition.</description>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline Measurement</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="88.1" spread="13.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Measurement at 4-5 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="87.1" spread="13.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage Body Fat</title>
        <description>To assess the potential beneficial effect of Cycloset on body fat content</description>
        <time_frame>Change from baseline to four to five months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Cycloset</title>
            <description>Drug - Cycloset Cycloset 2.4 -3.2 mg/day
Other Names:
Bromocriptine Mesylate Quick Release
Cycloset: Bromocriptine QR 0.8 mg tablet 0.8 mg/day with dose increased to a maximum of 3.2 mg/day or as tolerated to a minimum of 2.4 mg/day Other names: Cycloset, B-QR</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage Body Fat</title>
          <description>To assess the potential beneficial effect of Cycloset on body fat content</description>
          <units>percentage body fat</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline Measurement</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39.1" spread="6.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Measurement at 4-5 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39.3" spread="7.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Blood Pressure</title>
        <description>To assess the potential beneficial effect of Cycloset on blood pressure.</description>
        <time_frame>Change from baseline to four to five months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Cycloset</title>
            <description>Drug - Cycloset Cycloset 2.4 -3.2 mg/day
Other Names:
Bromocriptine Mesylate Quick Release
Cycloset: Bromocriptine QR 0.8 mg tablet 0.8 mg/day with dose increased to a maximum of 3.2 mg/day or as tolerated to a minimum of 2.4 mg/day Other names: Cycloset, B-QR</description>
          </group>
        </group_list>
        <measure>
          <title>Blood Pressure</title>
          <description>To assess the potential beneficial effect of Cycloset on blood pressure.</description>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Systolic pressure at baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="134" spread="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Systolic pressure at 4-5 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="126" spread="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diastolic pressure at baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="78" spread="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diastolic pressure at 4-5 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73" spread="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Arterial Blood Pressure</title>
        <description>To assess the potential beneficial effect of Cycloset on change in mean arterial blood pressure</description>
        <time_frame>Change from baseline to four to five months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Cycloset</title>
            <description>Drug - Cycloset Cycloset 2.4 -3.2 mg/day
Other Names:
Bromocriptine Mesylate Quick Release
Cycloset: Bromocriptine QR 0.8 mg tablet 0.8 mg/day with dose increased to a maximum of 3.2 mg/day or as tolerated to a minimum of 2.4 mg/day Other names: Cycloset, B-QR</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Arterial Blood Pressure</title>
          <description>To assess the potential beneficial effect of Cycloset on change in mean arterial blood pressure</description>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline Measurement</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97" spread="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Measurement at 4-5 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90" spread="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Arterial Stiffness (AS)</title>
        <description>To assess the potential beneficial effect of Cycloset on arterial stiffness. Arterial stiffness is calculated by the measurement of pulse pressure, where Pulse pressure = SBP - DBP (Where SBP is systolic blood pressure and DBP is diastolic blood pressure) The calculated value is used as a predictor of cardiovascular disease. Higher values indicate that cardiovascular disease is more likely.</description>
        <time_frame>Change from baseline to four to five months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Cycloset</title>
            <description>Drug - Cycloset Cycloset 2.4 -3.2 mg/day
Other Names:
Bromocriptine Mesylate Quick Release
Cycloset: Bromocriptine QR 0.8 mg tablet 0.8 mg/day with dose increased to a maximum of 3.2 mg/day or as tolerated to a minimum of 2.4 mg/day Other names: Cycloset, B-QR</description>
          </group>
        </group_list>
        <measure>
          <title>Arterial Stiffness (AS)</title>
          <description>To assess the potential beneficial effect of Cycloset on arterial stiffness. Arterial stiffness is calculated by the measurement of pulse pressure, where Pulse pressure = SBP - DBP (Where SBP is systolic blood pressure and DBP is diastolic blood pressure) The calculated value is used as a predictor of cardiovascular disease. Higher values indicate that cardiovascular disease is more likely.</description>
          <units>au (arbitrary units)</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline Measurement</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.8" spread="4.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Measurement at 4-5 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.2" spread="3.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were captured from baseline to between 4 to 5 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Cycloset</title>
          <description>Drug - Cycloset Cycloset 2.4 -3.2 mg/day
Other Names:
Bromocriptine Mesylate Quick Release
Cycloset: Bromocriptine QR 0.8 mg tablet 0.8 mg/day with dose increased to a maximum of 3.2 mg/day or as tolerated to a minimum of 2.4 mg/day Other names: Cycloset, B-QR</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Orthostatic Hypotension</sub_title>
                <description>Low blood pressure when standing up too quickly</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Light-headedness</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Mariam Alatrach</name_or_title>
      <organization>University of Texas Health San Antonio</organization>
      <phone>210-358-7220</phone>
      <email>alatrach@uthscsa.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

